Skip to content

AI Models for Non-invasive Glycaemic Event Detection Using ECG in Type 1 Diabetics

Development and Validation of Artificial Intelligence Models for Non-invasive Glycaemic Event Detection Using ECG in Type 1 Diabetics

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05461144
Enrollment
30
Registered
2022-07-15
Start date
2022-09-30
Completion date
2027-05-01
Last updated
2022-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Disease

Keywords

Endochrine

Brief summary

This observational study aims to recruit up to thirty T1DM patients from a diabetic outpatient clinic at the University Hospital Coventry and Warwickshire for a two-phase study. The first phase involves attending an inpatient protocol for up to thirty-six hours in a calorimetry room at the Human Metabolism Research Unit under controlled conditions, followed by a phase of free-living, for up to three days, in which participants will go about their normal daily activities without restriction. Throughout the study, the participants will wear commercially available wearable sensors to measure and record physiological signals (e.g., electrocardiogram and continuous glucose monitor). Data collected will be used to develop and validate an AI model using state-of-the-art deep-learning methods for the purpose of non-invasive glycaemic event detection.

Detailed description

The study volunteers will be asked to an attend an 'inpatient' facility for up to 36 hrs dedicated to advanced metabolic measurement (HMRU). They will be asked to consume prepared meals of varying macronutrient content as part of a balanced diet, and performed prescribed physical activity. During this time the volunteers will be measured by instrumentation which will investigate the chemical concentration in respired gases (e.g. whole-body calorimeters, metabolic carts); bloods, saliva and urine samples will be taken. If the participant then wishes, we will ask them to continue to wear the wearable devices in a home setting for a maximum one week. The data derived from this study will allow new tools and mathematical models to be developed that can be used to analyse and simulate patient metabolic response. It is envisaged this study will give further evidence to support future research into glucose utilisation in diseased metabolic populations.

Interventions

None listed

Sponsors

University of Warwick
CollaboratorOTHER
University Hospitals Coventry and Warwickshire NHS Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

The study will be open to all individuals living independently, over 18 years without acute illness or ongoing clinical investigation, or volunteers with a stable medical condition may be included. Volunteers with an ongoing medical condition will only be included after detailed consultation with our clinical and dietetics members of the team; however, it is imperative that volunteers are able to provide written informed consent.

Exclusion criteria

Whilst the study employs a deliberately open inclusion criterion, the following exclusion measures will be employed: * Children (under 18 yrs) * Any adult who lacks decisional capacity * Claustrophobia, isolophobia, recent abnormal exercise, radiation exposure within the preceding 24 hours of entering the whole-body calorimeter and feeling unwell in any way. * Needle phobia * Any medical/endocrine problem that could affect energy expenditure (e.g. thyroid problems, Cushing's syndrome) * Chronic inflammatory disorders like rheumatoid arthritis, or long term use of steroids or other immunomodulators like cyclosporine, azathioprine. * Beta blockers * Currently actively losing weight * Depression or any psychiatric illness

Design outcomes

Primary

MeasureTime frameDescription
Interstitial GlucoseFor the duration of the study, up to 5 daysAs measured by a continuous glucose monitor \[NOTE\] Observational study thus a key measurement not a true outcome measure.

Secondary

MeasureTime frameDescription
ECG -Interval across different fiducial pointsFor the duration of the study, up to 5 daysAs measured by an ambulatory ECG device \[NOTE\] Observational study thus a key measurement not a true outcome measure. The interval across different fiducial points (P.Q.R,S,T) is one of the features that are useful to quantify the difference in ECG signals for different glycaemic events.
ECG - Slope across different fiducial pointsFor the duration of the study, up to 5 daysAs measured by an ambulatory ECG device \[NOTE\] Observational study thus a key measurement not a true outcome measure. The Slope across different fiducial points (P.Q.R,S,T) is one of the features that are useful to quantify the difference in ECG signals for different glycaemic events.
ECG - Indices of Heart Rate VariabilityFor the duration of the study, up to 5 daysAs measured by an ambulatory ECG device \[NOTE\] Observational study thus a key measurement not a true outcome measure. Heart rate variability (HRV) is the fluctuation in the time intervals between adjacent heartbeats. There are several indices that are useful to quantify the difference in ECG signals for different glycaemic events such as Ultra Low Frequency (ULF) (≤0.003 Hz), Very Low Frequency (VLF) (0.0033-0.04 Hz), Low Frequency (LF) (0.04-0.15 Hz) and High Frequency (HF) (0.15-0.4 Hz)
Blood Pressure (Systolic and Diastolic)For the duration of the study, up to 5 daysAs measured by an ambulatory blood pressure device \[NOTE\] Observational study thus a key measurement not a true outcome measure.

Contacts

Primary ContactJohn G Hattersley, PhD
john.hattersley@uhcw.nhs.uk+44 (0) 24 7696 6068
Backup ContactLeandro Pechhia, PhD
L.Pecchia@warwick.ac.uk+44 (0) 24 7657 3383

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026